Grancha S, Estellés A, Gilabert J, Chirivella M, España F, Aznar J
Research Center, Department of Pathology, La Fe Universitary Hospital, Valencia, Spain.
Thromb Haemost. 1996 Nov;76(5):761-7.
An increase in plasma plasminogen activator inhibitors (PAIs), fundamentally PAI type 2 (PAI-2), has been described in normal pregnancy probably because the placenta is the main source of the high plasma levels of this protein. Although we have previously described plasmatic alterations of these inhibitors in pregnancies complicated with intrauterine fetal growth retardation (IUGR), no reports have been published about placental PAI-2 mRNA expression. In the present study, the placental PAI-2 expression determined in pregnancies complicated with IUGR and in severe preeclamptic patients was compared with that of normal pregnancies in order to identify the placental cell types expressing PAI-2 and to determine whether the production of PAI-2 is altered in placentas from IUGR. In situ hybridization analyses show that the syncytiotrophoblasts are the cells with the greatest PAI-2 expression in placenta. We report that the significant decrease in plasma and placental PAI-2 levels in IUGR groups is fundamentally due to a diminished expression of PAI-2 mRNA in placenta.
正常妊娠时血浆纤溶酶原激活物抑制剂(PAIs),主要是2型PAI(PAI - 2)会增加,这可能是因为胎盘是这种蛋白质血浆高水平的主要来源。尽管我们之前已经描述了这些抑制剂在合并宫内胎儿生长受限(IUGR)的妊娠中的血浆改变,但关于胎盘PAI - 2 mRNA表达尚无报道。在本研究中,将合并IUGR的妊娠和重度子痫前期患者的胎盘PAI - 2表达与正常妊娠进行比较,以确定表达PAI - 2的胎盘细胞类型,并确定IUGR胎盘组织中PAI - 2的产生是否改变。原位杂交分析表明,合体滋养层细胞是胎盘中PAI - 2表达最高的细胞。我们报告,IUGR组血浆和胎盘PAI - 2水平的显著降低主要是由于胎盘中PAI - 2 mRNA表达减少。